MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:32Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antivirals]]
			[[Category:Nucleoside analogs]]
			[[Category:Anti-herpesvirus agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #98

2026-05-23T03:46:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #98

New page

{{MedTemplate
| generic = Valacyclovir
| brand = Valtrex
| structure =
| classes = [[:Category:Antivirals|Antiviral]], [[:Category:Nucleoside_analogs|Nucleoside analog (prodrug)]], [[:Category:Anti-herpesvirus_agents|Anti-herpesvirus agent]]
| uses = <vote slug="genital-herpes-use">Genital herpes (HSV-1/2): episodic treatment and suppression</vote>, <vote slug="herpes-labialis-use">Herpes labialis (cold sores)</vote>, <vote slug="herpes-zoster-use">Herpes zoster (shingles)</vote>, <vote slug="varicella-use">Varicella (in adolescents/adults)</vote>
| starting_dose = Initial genital herpes 1 g PO BID × 10 days; recurrent 500 mg BID × 3 days; suppression 500 mg-1 g PO daily; zoster 1 g TID × 7 days
| preparations = 500 mg, 1 g tablets
| fda_max = 3 g/d (zoster)
| pill_id =
| routes = Oral
| onset = Symptom relief within 24-48 hours
| duration = 8 hours per dose
| halflife = ~3 hours (acyclovir, the active metabolite); longer in renal impairment<ref name="valtrex-label">FDA Prescribing Information, Valtrex (valacyclovir HCl), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020487s014lbl.pdf</ref>
| bioavailability = ~55% bioavailability of acyclovir after valacyclovir oral (vs ~20% from oral acyclovir directly)<ref name="valtrex-label" />
| pregnancy = Widely used in pregnancy when antiviral indicated; reassuring registry data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="valacyclovir-mech-claim">Valacyclovir is the L-valyl ester prodrug of acyclovir, exploiting the intestinal PEPT1 transporter to achieve substantially higher oral bioavailability than acyclovir itself; first-pass hepatic and intestinal hydrolysis releases acyclovir, which is then phosphorylated by viral thymidine kinase and host kinases to acyclovir triphosphate, a chain-terminating inhibitor of viral DNA polymerase selectively in HSV/VZV-infected cells.</vote> Selectivity comes from the viral-kinase-only initial phosphorylation step, which is why uninfected cells generate minimal active drug<ref name="valtrex-label" />. Dose-adjust by renal function; rare crystalline nephropathy with rapid IV acyclovir.
}}

== References ==
<references />

Valacyclovir - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #98